News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Shattuck Labs
NEWS
JOBS
IN THE PRESS
NEWS
Layoffs
Shattuck Labs to Lay Off 40% of Workforce
As it shifts focus to a death receptor 3 (DR3) antagonist antibody, Shattuck Labs is cutting a significant number of employees before the end of the year.
October 1, 2024
·
2 min read
·
Angela Gabriel
Deals
4 Biotech IPOs this Week: Kronos, Shattuck, Spruce and Aziyo
It’s been a fairly busy week for biotech initial public offerings (IPOs) with four announcing their list pricing. Here’s a look.
October 9, 2020
·
4 min read
·
Mark Terry
JOBS
Currently, there are no jobs for this company on BioSpace
Browse all jobs
here
Oops!
There was an issue retrieving the jobs list. Please reload the page to view more jobs.
Title
Location
Company Name
Desc
View details
IN THE PRESS
Press Releases
Shattuck Labs Announces Participation in Upcoming December Conferences
November 25, 2024
·
1 min read
Press Releases
Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 15, 2024
·
8 min read
Press Releases
Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway
October 1, 2024
·
9 min read
Business
Shattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 1, 2024
·
10 min read
Press Releases
Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference
July 31, 2024
·
1 min read
Drug Development
Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) & TP53 mutant AML Patients
June 14, 2024
·
11 min read
Bio NC
Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML)
June 10, 2024
·
5 min read
Bio NC
Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress
June 6, 2024
·
5 min read
Drug Development
Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) AML Patients at the EHA 2024 Congress
May 14, 2024
·
7 min read
Business
Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 2, 2024
·
11 min read
